Explore peer-reviewed research articles, clinical trials, and molecular pathways in inflammatory diseases
Discover how venetoclax, a BCL-2 inhibitor, shows promise in treating systemic chronic active Epstein-Barr virus disease (sCAEBV) through dual anti-tumor and anti-inflammatory effects.